The phytochemical resveratrol has undergone extensive preclinical investigation for its putative cancer chemopreventive properties. Low systemic availability of the parent compound due to rapid and extensive metabolism, may confound its usefulness as a potential agent to prevent malignancies in organs remote from the site of absorption. Micronization allows increased drug absorption, thus increasing availability. Here we describe a pilot study of SRT501, micronized resveratrol, given at 5.0 g daily for 14 days, to patients with colorectal cancer and hepatic metastases scheduled to undergo hepatectomy. The purpose of the study was to assess the safety, pharmacokinetics and pharmacodynamics of the formulation. SRT501 was found to be well tolerated. Mean plasma resveratrol levels following a single dose of SRT501 administration were 1942±1422 ng/mL, exceeding those published for equivalent doses of non-micronized resveratrol by 3.6-fold. Resveratrol was detectable in hepatic tissue following SRT501 administration (up to 2287 ng/g).
Introduction
Resveratrol (3, 5, 4 '-trihydroxy-trans-stilbene) is a phytoalexin produced by certain plants when damaged by pathogens such as bacteria or fungi. It occurs in the skin of red grapes and in peanuts, and has been investigated extensively with respect to its putative cancer chemopreventive properties. Resveratrol is thought to mediate, at least in part, the purported disease-preventing actions of red wine and is also considered to prevent cardiovascular disease and morbidity associated with obesity and old age [1] [2] [3] . The numerous pharmacological properties of resveratrol and the suggestion that it may be a calorie-restriction mimetic which can prolong life, has engendered considerable interest by the lay press. An abundance of data obtained in cells in vitro and in pre-clinical models has highlighted a plethora of potential mechanisms by which resveratrol may prevent malignancies, predominantly those germane to cell survival and proliferation [4] including p53-dependant apoptosis [5] and cell cycle arrest [6] . However, robust clinical data remain scarce. Recent clinical pilot studies of resveratrol, in which it was administered at single or repeat doses of up to 5.0 g daily, focussed on its safety, pharmacokinetic (PK) properties and the analysis of potential efficacy biomarkers [4, [7] [8] [9] [10] [11] [12] [13] . PK profiles of resveratrol in healthy volunteers revealed rapid and extensive metabolism to resveratrol-4'-Oglucuronide, resveratrol-3'-O-glucuronide and resveratrol-3-O-sulfate following oral administration of either a single [8] or repeated daily doses [9] of 0.5 to 5.0 g.
Despite detection of relatively high resveratrol concentrations in the colorectal tissue of patients, its systemic availability is severely reduced by its avid metabolism.
Consequently, although resveratrol has demonstrated activity against a wide variety of malignancies in vitro (including bowel, breast, bladder, prostate, liver and thyroid) and in vivo (reviewed in [3, [14] [15] [16] ), it is likely that poor bioavailability may limit Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 16, 2011; DOI: 10.1158 /1940 efficacy at sites distant to the GI tract. Despite this, there is evidence to suggest that resveratrol elicits chemopreventive and therapeutic effects in pre-clinical models of liver cancer (reviewed in [17] ), alluding to potential for efficacy against hepatocarcinogenesis and malignancies that preferentially metastasise to the liver.
Due to the poor aqueous solubility exhibited by resveratrol, digestive absorption is greatly influenced by drug dissolution rate. In an effort to increase absorption across the gastro-intestinal tract and thus systemically available parent compound, there has been considerable interest in the pharmaceutical manipulation of resveratrol.
Decreasing the particle size of such chemicals can improve their rate of dissolution and thus their absorption [18] . Therefore, the aim of this clinical study was to investigate whether consumption of SRT501, a micronized resveratrol formulation designed by Sirtris, a GSK Company (Cambridge, MA, USA) is safe and generates measurable and pharmacologically active levels of parent agent in the circulation and in the liver. There is currently no clinical data available that determines resveratrol concentrations in human tissues other than the colon. To this end patients with colorectal cancer earmarked to undergo resection of liver metastases were recruited into a pilot study. They ingested either placebo or SRT501 on 14 consecutive days prior to surgery, and levels of resveratrol were quantified in blood and hepatic resection tissue. Potential pharmacodynamic effects of SRT501 were investigated by comparing the expression/activation of candidate protein biomarkers intrinsically associated with cell survival and apoptosis in the circulation and tissue of patients who received the agent and those who were on placebo. 
Methods

Resveratrol formulation
Study design
The study was a phase I, randomised (2:1), double-blind clinical trial. Six subjects were randomised to receive SRT501, and three placebo (titanium dioxide).
Interventions were provided in clinical kits as a powder and reconstituted as described above. Patients ingested the formulation pre-operatively daily for a minimum of 10 and a maximum of 21 days, dependent upon surgical scheduling.
Plasma samples for PK assessment were obtained on days 1 and 2, and on the day of surgical resection. Plasma for PD assessment was obtained pre-dose, immediately prior to, and during surgery. Diseased and normal adjacent hepatic tissue was resected 6-7 h after the last dose. Participants completed a daily adverse event (AE) diary which was assessed using the NCI Common Toxicity Criteria v3. Of the nine patients recruited, seven completed the study, one died from post-operative complications, and one ceased administration early due to AEs (diarrhoea). PK samples were obtained from all nine subjects. The primary objectives of the study were to determine safety and tolerability of SRT501 and resveratrol pharmacokinetics. The secondary objectives were to explore potential pharmacodynamic changes elicited by SRT501 in blood and tissues.
Sample collection
Blood samples were collected prior to administration on day 1, for PK at 0.25, 0.5, 1, 2, 4, 8, 24 h post the first dose, and prior to, and during surgery. Plasma (sodium heparin tubes) and serum were obtained and stored at -80 °C until analysis. Tissues were harvested from resected material, part of which was formalin-fixed and paraffinembedded, and part immediately frozen and stored at -80 °C until analysis. (v/v/v)). The elution gradient was A85% B15% to A5% B95% for 4 min. Resveratrol was characterised by electrospray mass spectrometry (negative ionisation mode) with ion spray voltage -4500 V, declustering potential -25 V, focusing potential -30 V, entrance potential -12 V, collision energy -27 V, collision exit potential 40 V and temperature 550 °C. Lower limit of quantitation (LLOQ) was 5 ng/mL and upper limit of quantitation (ULOQ) 1000 ng/mL. Tissue samples were minced on ice and ~100 mg was used for analysis. Acidified methanol (ascorbic acid:methanol:formic acid, 50:50:0.025) (5 μL) containing resveratrol-13 C 6 as an internal standard, 100 μL matrix green beads and 500 μL ethanol was added to each sample, the mixture vortexed and left on ice (10 min). Peek pre-column 0.5 μm filter. The eluant was as for the plasma analysis; gradient elution was over 6.5 min from A70% B30% to A0% B100%, then back to A70% B30%. MS conditions were as above except: ion spray voltage -4500 V, declustering potential -120 V, entrance potential -10 V, collision energy -27 V, collision exit potential -10 V and temperature 700 °C. For tissue samples, LLOQ was set at 2.5 ng/g and ULOQ at 500 ng/g. Data collection was performed using Analyst version Statistical analyses for pharmacodynamic data were undertaken using SPSS 16.0 for Windows. Means were compared via one way, one sided ANOVA followed by Tukey's post hoc test. A p value of less than 0.05 was deemed significant. 
Analysis of cell proliferation and apoptosis
Results
Safety of SRT-501
Resveratrol pharmacokinetics and concentration in liver tissue
Effect of SRT501 on pharmacodynamics
Potential effects of SRT501 on processes relevant to cell survival and apoptosis were measured in plasma and tissue. There was no difference between patients who received placebo or SRT501 in terms of plasma/serum levels of prostaglandin E2 (PGE-2) and vascular endothelial growth factor (VEGF) (not shown). Tissue samples were analyzed by immunohistochemistry, ELISA or western blot for SRT501-induced changes to levels of IGF-1, Ki67, phospho Akt (ser473), Akt1, phospho-GSK3, GSK3, phospho ERK, ERK, phospho-JNK, JNK, beta-catenin, survivin, BCL2, Bax or PARP. In all cases there were no significant differences between placebo and SRT501 (data not shown). Apoptosis, as reflected by immunohistochemistry for cleaved caspase 3 in tumor tissue, was significantly increased by 39% (to 1.44% total apoptotic cells, p=0.038) in patients on SRT501 compared to those taking placebo (figure 2).
Discussion
This trial represents the first description of pharmacokinetic parameters for resveratrol after ingestion of SRT501, micronized resveratrol, in subjects with colorectal cancer. The dose of resveratrol employed (5.0 g) is equivalent to one of the dose levels at which non-micronized resveratrol was recently administered to healthy volunteers [9] . In the healthy volunteer study, ten subjects on 5.0 g of the non-micronized resveratrol reported twenty AEs possibly or probably related to ingestion of resveratrol capsules, which compares with seventeen AEs reported for six patients who received SRT501. The two formulations therefore seem to cause a similar incidence of AEs, although in the previous study non-micronized resveratrol was administered for a longer duration (29 days) than SRT501. All AEs reported following SRT501 administration were mild, whilst two of the ten healthy volunteers on non-micronized resveratrol, presented with moderate and one with severe gastrointestinal AEs [9] . This comparison provides the possibility that SRT501 formulated as a suspension may be better tolerated than non-micronized resveratrol given as ten 0.5 g capsules per day. Since micronized resveratrol was expected to afford higher systemic concentrations [19] , this finding also suggests that ingestion of a large number of capsules or the presence of non-absorbed resveratrol in the GI tract may be responsible for the adverse effects, rather than the actual plasma concentrations achieved.
The pharmacokinetic analysis revealed that the mean plasma C max for resveratrol measured after ingestion of SRT501 (mean 1942 ng/mL , CV:73.3%) was 3.6-fold higher than that achieved following a single dose of non-micronized resveratrol in healthy volunteers (mean 538.8 ng/mL (CV:72.5%) [8] , consistent with the superior bioavailability of resveratrol when administered as SRT501 compared to non-micronized agent. The time taken to reach the C max for resveratrol was 2.8 h in the case of SRT501 compared to 1.5 h for non-micronized resveratrol [8] . were not able to confirm these effects via other pharmacodynamic markers, this may be due to low sensitivity of the techniques used. Mechanisms by which low concentrations of resveratrol have been observed to induce apoptotic and antiproliferative effect in vitro include induction of Fas redistribution and its association with the death-inducing signalling (DISC) complex [20] , and via inhibition of wnt signalling and subsequent decrease in nuclear β-catenin localisation [21] . In a preclinical model of diethylnitrosamine-initiated hepatocarcinogenesis, significant resveratrol-mediated apoptosis likely resulted from increased Bax expression and consequent increase in the Bax:Bcl2 ratio [22] . Whilst tissue resveratrol levels were not determined in this study, extrapolation of data from rodent PK studies [23, 24] would suggest hepatic resveratrol concentrations necessary for apoptosis induction, to be only moderately higher than the maximum achieved in the SRT501 study described here. This is the first demonstration that resveratrol can reach potentially active concentrations in human tissues that are distant to the GI tract.
Concentrations
In summary, the results of this pilot study of SRT501 allow three conclusions: i. its daily consumption for 14 days seems to be well tolerated in colorectal cancer patients, ii. C max for SRT501 was higher than reported for equivalent dose of nonmicronised resveratrol, iii. its ingestion furnished measurable resveratrol levels in a tissue distant to the GI tract (in particular the liver), and these concentrations were accompanied by a significant pharmacological effect.
Micronized resveratrol, as exemplified by SRT501, warrants further clinical exploration in larger cohorts of subjects, in order to test the hypothesis that resveratrol may be of use as a cancer chemopreventive or chemotherapeutic agent. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Table 2 . Adverse event listings deemed to be possibly or probably related to SRT501/placebo intervention.
